Vaxart Receives Up To $453M Award From BARDA For Phase 2b Study Of Oral COVID-19 Vaccine
Portfolio Pulse from Benzinga Newsdesk
Vaxart has received up to $453 million from BARDA for a Phase 2b study of its oral COVID-19 vaccine. The initial $65.7 million will fund the study start-up, with the remaining $387.2 million contingent on further study approval. Enrollment is expected to begin in summer 2024, with interim analysis by Q1 2025.
June 13, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxart has secured up to $453 million from BARDA for a Phase 2b study of its oral COVID-19 vaccine. The funding will support the study start-up and further phases, with enrollment expected in summer 2024 and interim analysis by Q1 2025.
The significant funding from BARDA is a strong positive signal for Vaxart's oral COVID-19 vaccine development. The initial $65.7 million will enable the start-up of the study, and the potential for an additional $387.2 million indicates confidence in the vaccine's progress. This news is likely to boost investor sentiment and positively impact VXRT's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100